Tuberculosis after hematopoietic cell transplantation: retrospective study on behalf of the infectious diseases working party of the EBMT.

IF 4.5 2区医学 Q1 HEMATOLOGY

Bone Marrow Transplantation Pub Date : 2025-02-25 DOI:10.1038/s41409-025-02530-4

Joanna Drozd-Sokołowska, Gloria Tridello, Inge Verheggen, Musa Karakukcu, Nour Ben Abdeljelil, Anca Colita, Mahmoud Aljurf, Nicolaus Kröger, Gulyuz Ozturk, Jakob Passweg, Massimiliano Gambella, Marina Popova, Lucía López Corral, Alina Tanase, Agnieszka Piekarska, Mohsen Al Zahrani, Muhlis Cem Ar, Grzegorz Basak, Annoek E C Broers, Kristina Carlson, Andrew Clark, Maura Faraci, Pavel Jindra, Gergely Kriván, Sophie Ducastelle Lepretre, Stephan Mielke, Judith Niederland, Fabrizio Pane, Katharine Patrick, John A Snowden, Irfan Yavasoglu, Marco Zecca, Anna Waszczuk-Gajda, Lotus Wendel, Nina Knelange, Rafael de la Camara, Lidia Gil, Malgorzata Mikulska, Dina Averbuch, Jan Styczynski

{"title":"Tuberculosis after hematopoietic cell transplantation: retrospective study on behalf of the infectious diseases working party of the EBMT.","authors":"Joanna Drozd-Sokołowska, Gloria Tridello, Inge Verheggen, Musa Karakukcu, Nour Ben Abdeljelil, Anca Colita, Mahmoud Aljurf, Nicolaus Kröger, Gulyuz Ozturk, Jakob Passweg, Massimiliano Gambella, Marina Popova, Lucía López Corral, Alina Tanase, Agnieszka Piekarska, Mohsen Al Zahrani, Muhlis Cem Ar, Grzegorz Basak, Annoek E C Broers, Kristina Carlson, Andrew Clark, Maura Faraci, Pavel Jindra, Gergely Kriván, Sophie Ducastelle Lepretre, Stephan Mielke, Judith Niederland, Fabrizio Pane, Katharine Patrick, John A Snowden, Irfan Yavasoglu, Marco Zecca, Anna Waszczuk-Gajda, Lotus Wendel, Nina Knelange, Rafael de la Camara, Lidia Gil, Malgorzata Mikulska, Dina Averbuch, Jan Styczynski","doi":"10.1038/s41409-025-02530-4","DOIUrl":null,"url":null,"abstract":"<p><p>Tuberculosis (TB) is rare following hematopoietic cell transplantation (HCT). In this multinational retrospective study, we report the frequency, characteristics, and outcome of TB following HCT performed during 2000-2019. Fifty-two patients (35 (67%) males, 15 (29%) children) from 24 centers developed TB following allogeneic (n = 47) or autologous (n = 5) HCT; with the relative frequency of 0.21% and 0.025%, respectively. Forty (77%) were bacteriologically, 12 (23%) clinically confirmed. The median time from HCT to TB was 135 (range, 16-3225) days. Eighteen (35%) patients with extrapulmonary TB (mainly involving lymph nodes and liver/spleen) were significantly younger, developed TB shorter after HCT, more often had inherited underlying disease, and received immunosuppressive therapy at TB diagnosis as compared to pulmonary TB. Five (22%) of 23 patients with drug-susceptibility testing performed, were resistant to at least one anti-TB drug. Treatment success was achieved in 38/50 (76%) of treated patients. One-year overall survival reached 75.7% and the 1-year cumulative incidence of TB-associated death was 18.1%. Concluding, TB is a rare, albeit severe complication, which can develop any time after HCT, frequently involves extrapulmonary sites, and results in high mortality rates. High proportion of drug-resistant TB warrants routine susceptibility testing.</p>","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5000,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bone Marrow Transplantation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41409-025-02530-4","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Tuberculosis (TB) is rare following hematopoietic cell transplantation (HCT). In this multinational retrospective study, we report the frequency, characteristics, and outcome of TB following HCT performed during 2000-2019. Fifty-two patients (35 (67%) males, 15 (29%) children) from 24 centers developed TB following allogeneic (n = 47) or autologous (n = 5) HCT; with the relative frequency of 0.21% and 0.025%, respectively. Forty (77%) were bacteriologically, 12 (23%) clinically confirmed. The median time from HCT to TB was 135 (range, 16-3225) days. Eighteen (35%) patients with extrapulmonary TB (mainly involving lymph nodes and liver/spleen) were significantly younger, developed TB shorter after HCT, more often had inherited underlying disease, and received immunosuppressive therapy at TB diagnosis as compared to pulmonary TB. Five (22%) of 23 patients with drug-susceptibility testing performed, were resistant to at least one anti-TB drug. Treatment success was achieved in 38/50 (76%) of treated patients. One-year overall survival reached 75.7% and the 1-year cumulative incidence of TB-associated death was 18.1%. Concluding, TB is a rare, albeit severe complication, which can develop any time after HCT, frequently involves extrapulmonary sites, and results in high mortality rates. High proportion of drug-resistant TB warrants routine susceptibility testing.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Bone Marrow Transplantation 医学-免疫学

CiteScore

8.40

自引率

8.30%

发文量

337

审稿时长

6 months

期刊介绍： Bone Marrow Transplantation publishes high quality, peer reviewed original research that addresses all aspects of basic biology and clinical use of haemopoietic stem cell transplantation. The broad scope of the journal thus encompasses topics such as stem cell biology, e.g., kinetics and cytokine control, transplantation immunology e.g., HLA and matching techniques, translational research, and clinical results of specific transplant protocols. Bone Marrow Transplantation publishes 24 issues a year.